dosing difference between semaglutide and tirzepatide vs. for Weight Loss Standard Dose vs Microdose GLP-1:

Comorbidities diabetes, heart disease, or fatty liver disease may influence drug choice

Medication is priced separately and confirmed after provider consultation

1) Targets Fat Metabolism (AOD 9604) Supports pathways commonly associated with: fat breakdown stubborn fat reduction support lean tissue protection during dieting 2) Supports Energy + Metabolic Flexibility (MOTS-c) Supports: mitochondrial energy production better fuel utilization (carbs + fats) metabolic resilience during stress, dieting, or busy seasons 3) Supports Visceral Fat + Midsection Goals (Tesamorelin) Supports: visceral fat reduction in certain individuals midsection-focused body composition goals metabolic pathway support under provider guidance 4) Supports Recovery + Sleep (Ipamorelin) Supports: deeper, more restorative sleep better recovery between workouts improved consistency (because you feel better while leaning out) In simple terms: AOD + MOTS-c help the metabolism feel on, Tesamorelin supports midsection/visceral fat goals, and Ipamorelin helps you recover and sleep so you can stay consistent

The GLP-1 receptor agonist market size was exhibited at USD 36.95 billion in 2023 and is projected to hit around USD 261.19 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2024 to 2033